Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Clin Endosc > Volume 58(3); 2025 > Article
Review Remimazolam, a novel drug, for safe and effective endoscopic sedation
Jae Min Lee1orcid, Yehyun Park2orcid, Dong Won Ahn3orcid, Jun Kyu Lee4orcid, Kwang Hyuck Lee5orcid
Clinical Endoscopy 2025;58(3):370-376.
DOI: https://doi.org/10.5946/ce.2024.026
Published online: January 14, 2025

1Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea

2Department of Internal Medicine, Ewha Womans University Seoul Hospital, Seoul, Korea

3Department Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea

4Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Korea

5Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea

Correspondence: Kwang Hyuck Lee Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea E-mail: lkhyuck@gmail.com
• Received: February 7, 2024   • Revised: May 7, 2024   • Accepted: May 8, 2024

© 2025 Korean Society of Gastrointestinal Endoscopy

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 4,708 Views
  • 376 Download
  • 1 Crossref
prev next
Full Article

Download PDF Download PDF

  • Remimazolam is a novel benzodiazepine with unique pharmacokinetic and pharmacodynamic properties, making it an ideal candidate for sedation during endoscopic procedures. Distinguished by its rapid onset and short duration of action, remimazolam offers a safer and more efficient alternative to traditional sedatives, such as midazolam and propofol, with fewer side effects, such as hypotension, bradycardia, and respiratory depression. This article reviews the characteristics of remimazolam and its practical advantages, including ease of use, quick recovery time, and minimal residual sedation, emphasizing its potential to improve patient safety and procedural efficiency in clinical endoscopy settings.
  • Keywords: Conscious sedation; Endoscopy; Hypnotics and sedatives; Remimazolam
Sedative medications are administered to patients during procedures to enable the effective performance of tests or treatments that may be painful or uncomfortable.1 According to the American Society of Anesthesiologists (ASA), sedation depth can be categorized into four levels: minimal sedation, moderate sedation (or conscious sedation), deep sedation, and general anesthesia. Moderate sedation is recommended to ensure the safety and efficiency of endoscopic procedures. During moderate sedation, patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No intervention is required to maintain a patent airway, and adequate spontaneous ventilation persists.2
The degree of sedation is continuous and nongradual, and the extent to which each patient is sedated varies significantly from person to person. Additionally, the possibility of unexpected drug responses highlights the importance of effective sedation during endoscopy. The characteristics of ideal sedatives include ease of use, rapid onset of action, rapid postadministration recovery, and minimal residual sedation.3 Rapid onset and recovery times contribute to the efficient operation of the endoscopy and recovery rooms, whereas minimal residual sedation increases patient safety upon leaving these areas. Midazolam, a benzodiazepine, is preferred because of its short onset of sedation, low risk of thrombophlebitis, and amnesic effects.4 However, the active metabolites of midazolam may prolong sedation time, especially with cumulative administration.5 Propofol, also known as 2,6-diisopropylphenol, is an intravenous (IV) anesthetic used for the induction and maintenance of general anesthesia.6 It is a preferred sedative for gastrointestinal endoscopy because of its faster recovery time than midazolam. However, side effects include anaphylaxis, bronchospasm, angioedema, temporary airway obstruction leading to apnea, and unstable blood pressure.
Remimazolam besylate, also known simply as remimazolam and marketed as Byfavo (Hana Pharm) in Korea, BYFAVO (Acacia Pharma) in the United States of America (USA), Anerem (Mundipharma) in Japan, Byfavo (PAION AG) in the European Union, and Ruima (Yichang Humanwell) in China in China, is a benzodiazepine sedative. It is characterized by rapidly hydrolyzed ester linkages.7 Unlike midazolam, remimazolam produces inactive metabolites and has been developed as a soft drug that offers rapid action and a predictable recovery time.8,9 In the USA, remimazolam is approved for sedation induction and maintenance in adults for procedures lasting less than 30 minutes.10 It has recently been approved in the European Union as a sedative for adults11 and is authorized in Korea for use in short-term procedures, including anesthesia and endoscopy. In this article, we summarized the characteristics of remimazolam and investigated its efficacy as a sedative in endoscopic procedures.
Remimazolam exerts its sedative effect by binding to the benzodiazepine binding site on γ-aminobutyric acid (GABA) receptors in the brain within the central nervous system.12 Unlike other benzodiazepines, remimazolam does not selectively affect specific GABA receptor subtypes. It is characterized by a high clearance rate, small steady-state volume of distribution (Vss), short elimination half-life, and first-order linear pharmacokinetics. A key study comparing remimazolam to midazolam found that the mean Vss of remimazolam was significantly smaller (34.8 L vs. 81.8 L for midazolam), and its elimination rate was about three times faster.10 The terminal half-life of remimazolam is notably shorter (0.75 hours) than that of midazolam (4.29 hours). Remimazolam undergoes rapid and extensive metabolism, predominantly by tissue esterases (chiefly liver carboxylesterase), into an inactive metabolite (CNS 7054) with a substantially lower affinity than its parent compound.
The drug is primarily excreted in urine, with over 80% detected as a metabolite and less than 1% remaining unchanged within 24 hours.13 During the elimination phase, over 90% of remimazolam binds to plasma proteins, mainly serum albumin, with a terminal half-life of 37 to 53 minutes independent of body weight. The context-sensitive half-life of remimazolam is shorter than that of midazolam but similar to that of propofol. In addition, it is relatively independent of infusion duration. The pharmacokinetic properties of remimazolam appear to be unaffected by chronic kidney disease, age, sex, race, or weight.14 However, patients with severe hepatic impairment (Child-Pugh class C) exhibited a higher area under the concentration-time curve and lower clearance than those with normal hepatic function.14 The pharmacokinetic properties were not significantly different between patients with normal hepatic function and those with mild/moderate hepatic dysfunction (Child-Pugh classes A and B).
Remimazolam, when administered intravenously, activates GABA-A receptors featuring γ-subunits. This activation leads to an influx of chloride ions, causing neuronal membranes to hyperpolarize, thereby diminishing neuronal activity.15 Its influence on GABA-A receptors spans multiple subtypes (α1, α2, α3, α5) and mirrors the action of midazolam, albeit without specific subtype selectivity. Clinical evaluation of the sedative properties of remimazolam, assessed using tools such as the electroencephalogram beta ratio and modified observer’s alertness/sedation (MOAA/S) scores, consistently show a swift onset and resolution of sedation, which vary in intensity and duration based on the administered dosage.16,17 Comparative studies have highlighted that remimazolam induces a more immediate and profound state of sedation than does midazolam, along with a more rapid return to alertness.16 The MOAA/S score rapidly decreased from 5 to less than 2, indicating a transition from complete alertness to a state approaching unconsciousness within five minutes of starting a 35-minute infusion of remimazolam. Complete alertness was regained within 19 min of infusion discontinuation.
Table 1 presents the results of two comparative studies on the effects of midazolam and remimazolam.18,19 A randomized double-blind study compared remimazolam with a placebo and open-label midazolam for sedation for outpatient colonoscopy in 461 patients, focusing on safety and efficacy.18 Remimazolam exhibited higher procedural success rates than placebo, necessitating fewer rescue medications and top-up doses, with a statistically significant difference in success rates. The time to achieve optimal sedation was shorter with remimazolam, and the patients experienced deeper sedation levels during the procedure. Recovery times were consistently shorter for remimazolam and patient recall of the procedure was similar across all groups, indicating effective sedation without significant effects on memory. The incidence of adverse events, particularly hypotension, was lower with remimazolam than with midazolam, with no significant differences in laboratory safety parameters between the treatment groups. In another multicenter, double-blind study, the safety and efficacy of remimazolam were compared with those of placebo and midazolam in the procedural sedation of patients classified as high-risk ASA III/IV undergoing colonoscopy.20 Remimazolam demonstrated superior efficacy in terms of procedural success (87.1%) compared with placebo (0%) and midazolam (13.3%), with a quicker onset of appropriate sedation and faster recovery to full alertness after colonoscopy. Patients treated with remimazolam required lower cumulative doses of fentanyl for pain control during the procedure and fewer rescue medications than patients in the other groups. The study concluded that remimazolam was safe and effective for procedural sedation in patients with high-risk ASA classifications undergoing colonoscopy, with a safety profile comparable to that of patients classified as low-risk.
Propofol is one of the most used agents for procedural sedation,21 and comparative studies have been conducted on the efficacy of propofol and remimazolam in endoscopy. Table 2 presents the results of comparative studies on the effects of propofol and remimazolam in older patients undergoing gastroscopy.22,23 In a recent meta-analysis that included seven randomized controlled trials, propofol demonstrated superior efficacy compared to remimazolam, whereas remimazolam showed superior safety.24 Propofol, acknowledged for its merits, including rapid onset, context-sensitive half-life, and predictable duration, is considered as useful as midazolam. Generally, it is well tolerated and favored owing to its quick recovery profile.4,25 However, because of its vasodilatory effects, propofol can induce severe hypotension, especially in older patients and those with cardiovascular diseases.26 In addition, the absence of a propofol antagonist requires caution in patients with respiratory depression.27 In contrast, remimazolam is less likely to cause severe respiratory depression.
A multicenter randomized controlled trial involving older patients (65–85 years) undergoing upper gastrointestinal endoscopy compared remimazolam, tosilate, and propofol administered in conjunction with fentanyl.28 The primary focus was on the sedation levels and incidence of hypotension, bradycardia, and respiratory depression. The study found that remimazolam had significantly lower rates of hypotension (36.5% vs. 69.6%), bradycardia (1.5% vs. 8.5%), and respiratory depression (4.5% vs. 10.0%) and caused less pain at the injection site than propofol. These findings suggest that remimazolam is safer for older patients undergoing deep sedation.
In another trial, a 95% effective dose (ED95) for the induction of sedation in older patients undergoing outpatient gastroscopy was determined using remimazolam and propofol in combination with remifentanil.29 The ED95 for remimazolam was significantly lower than that for propofol, and the incidence of adverse events was considerably lower in the remimazolam group than in the propofol group (40.6% vs. 83.1%). However, the remimazolam group had a higher incidence of hiccups and a marginally shorter median time to awakening than did the propofol group. Propofol and remimazolam have distinct advantages that merit consideration when selecting procedural sedatives during endoscopy. According to a recent meta-analysis, propofol showed a considerably shorter time to loss of consciousness and a higher success rate of sedation after the initial dose. Conversely, remimazolam significantly reduced the incidences of bradycardia, hypoxemia, and pain at the injection site.30 Remimazolam may be a safer and more suitable alternative to propofol for sedation during endoscopy, particularly in older patients.
The dose of remimazolam for inducing and maintaining sedation in adults is personalized and adjusted to attain the desired effect. The recommended dose for the induction of procedural sedation was 5 mg administered over 1 minute. If necessary, additional IV doses of remimazolam (2.5 mg) were administered over 15 seconds with a minimum interval of 2 minutes between each dose.8 For patients with an ASA-physical status (ASA-PS) score of III/IV, the induction dose would be reduced from 5 to 2.5 mg of remimazolam. Depending on the patient's condition, supplemental doses of 1.25 to 2.5 mg may be added as directed by the physician. In the European Union, when remimazolam is co-administered with opioids in adults under 65 years of age, the recommended dose is 5 mg for induction and 2.5 mg for maintenance,11 aligning with the recommendations in the USA. A starting remimazolam dose of 7 mg is recommended in the absence of concurrent opioid use. For patients with an ASA-PS score of III/IV, aged 65 years or older, or weighing less than 50 kg, an induction dose of 2.5 to 5 mg is recommended regardless of concomitant opioid medication, with subsequent doses of 1.25 to 2.5 mg.
The safety profile of remimazolam remains undefined as it is a newly introduced medication. Prescription guidelines for remimazolam caution against potential side effects during sedation, including hypoxia, bradycardia, and hypotension. Recent studies have reported anaphylaxis associated with remimazolam.24 It is possible that anaphylaxis could be caused by the excipient dextran-40 or remimazolam. Therefore, remimazolam should only be administered to individuals undergoing procedural sedation. Given the higher risk of anaphylaxis with rapid administration, careful consideration of both the dose and rate of administration is necessary. It is also important to continuously monitor the patient's vital signs not only during the sedation process but also throughout the entire period of recovery. The sedative effects of remimazolam can be counteracted by treatment with a benzodiazepine antagonist.31 The recommended initial dose of flumazenil is 0.2 mg to counteract benzodiazepine-induced sedation. This dose should be injected over 15 seconds to minimize side effects such as hypertension and anxiety. If the patient does not fully recover within 60 seconds, additional doses (0.2 mg) up to a maximum of 1 mg can be administered. The dosage is tailored based on the patient's response, with a maximum dose of 3 mg administered within an hour.32 Routine use of flumazenil to reverse remimazolam sedation is not recommended because of remimazolam’s potential for rebound sedation.33
Remimazolam is effective for inducing and maintaining procedural sedation, particularly during endoscopic procedures. It has emerged as a safe and efficacious alternative, showing substantial promise in replacing existing sedatives (Table 3). Midazolam and propofol are the preferred sedatives for procedural sedation during endoscopy.34,35 However, research on the effectiveness of remimazolam across all areas of endoscopy, including therapeutic procedures, is ongoing, and results are fully expected.36,37 With the introduction of remimazolam, there is potential for the development of updated guidelines that reflect the outcomes of current and forthcoming studies on remimazolam in endoscopy.
Remimazolam, a novel short-acting sedative that has emerged from ‘soft drug’ development, is highly effective in inducing and maintaining procedural sedation. Its benefits such as rapid action, predictable duration, stable hemodynamics, and independence from organ function make it promising for various clinical applications. It has shown high success and tolerability in endoscopic procedures, significantly improving onset and recovery times compared to other methods. Based on a thorough review of recent guidelines and multiple studies, remimazolam may be particularly beneficial in patients with cardiovascular instabilities, including unstable blood pressure or arrhythmias caused by other sedatives. Its rapid onset and predictable pharmacokinetics allow for a smoother induction and recovery period, making it a preferable option for effectively managing procedural stress and discomfort. These advantages suggest that remimazolam can be used to improve endoscopy room operations and sedation practices. Understanding the full benefits, including cost-effectiveness, requires a thorough pharmacoeconomic analysis. We believe that remimazolam holds great promise as a standard sedative. However, its efficacy and safety across different settings require validation through comprehensive studies.
Table 1.
Clinical trials of remimazolam for procedural sedation in patients undergoing colonoscopy
Clinical trial no. 1. Outpatient colonoscopy (n=461)
 Clinical trial no. 2. High risk colonoscopy (n=162)
Placebo+rescue Midazolam Remimazolam Placebo+rescue Midazolam Remimazolam
Procedure success (%) 1.7 25.2 91.3 0.0 13.3 87.1
Completion of procedure (%) 98.3 98.1 97.7 100.0 100.0 100.0
Rescue therapy not required (%) 5.0 35.9 96.6 0.0 20.0 90.3
Fully alert after end of procedure (min) 22.0 15.8 7.4 5.3 7.0 3.0
Ready for discharge after end of procedure (min) 53.2 27.9 42.7 No report No report No report
Back to normal after last dose (h) 9.5 9.2 5.5 No report No report No report
Table 2.
Remimazolam versus propofol for procedural sedation in elderly patients undergoing gastroscopy
Clinical trial no. 1. Upper gastrointestinal endoscopy in elderly patients (n=400)
 Clinical trial no. 2. Sedative-related adverse events in elderly patients undergoing gastroscopy (n=346)
Propofol Remimazolam Propofol Remimazolam
Sedation success (%) 100 100 100 99.4
Time to loss of consciousness (s) No data No data 64 (50–80) 70 (58–92)
Time to successful sedation (min) 2.1±0.4 2.1±0.4 No data No data
Time to fully alert (min) 9.8±3.7 9.3±3.7 13.8±4.2 15.1±4.1
Hypoxemia / apnea (%) 2 1 1.7 0.6
Hypotension (%) 50.9 32.4 69.6 36.5
Time to hospital discharge (min) No data No data 19.6±7.6 19.9±6.3

Data are presented as mean±standard deviation, unless otherwise indicated.

Table 3.
Characteristics of propofol, midazolam, and remimazolam
Characteristic Propofol Midazolam Remimazolam
Formulation Liquid Liquid Powder
Pain on intravenous injection Painful No pain No pain
Reversal agent No Flumazenil Flumazenil
Cardiovascular and respiratory suppression ++ +/- +/-
Active metabolite – + –
Onset time (min) <1 3–5 1–2
Recovery time (min) 10 20–80 10–40
Metabolism Hepatic/extrahepatic Hepatic Tissue esterase
  • 1. Hinkelbein J, Lamperti M, Akeson J, et al. European Society of Anaesthesiology and European Board of Anaesthesiology guidelines for procedural sedation and analgesia in adults. Eur J Anaesthesiol 2018;35:6–24.ArticlePubMed
  • 2. Practice guidelines for moderate procedural sedation and analgesia 2018: a report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology. Anesthesiology 2018;128:437–479.ArticlePubMed
  • 3. Brohan J, Goudra BG. The role of GABA receptor agonists in anesthesia and sedation. CNS Drugs 2017;31:845–856.ArticlePubMedPDF
  • 4. ASGE Standards of Practice Committee, Early DS, Lightdale JR, et al. Guidelines for sedation and anesthesia in GI endoscopy. Gastrointest Endosc 2018;87:327–337.ArticlePubMed
  • 5. Nishizawa T, Yoshida S, Toyoshima O, et al. Risk factors for prolonged hospital stay after endoscopy. Clin Endosc 2021;54:851–856.ArticlePubMedPMCPDF
  • 6. Faigel DO, Baron TH, Goldstein JL, et al. Guidelines for the use of deep sedation and anesthesia for GI endoscopy. Gastrointest Endosc 2002;56:613–617.ArticlePubMed
  • 7. Kilpatrick GJ. Remimazolam: non-clinical and clinical profile of a new sedative/anesthetic agent. Front Pharmacol 2021;12:690875.ArticlePubMedPMC
  • 8. Wesolowski AM, Zaccagnino MP, Malapero RJ, et al. Remimazolam: pharmacologic considerations and clinical role in anesthesiology. Pharmacotherapy 2016;36:1021–1027.ArticlePubMed
  • 9. Lee JM, Park Y, Park JM, et al. New sedatives and analgesic drugs for gastrointestinal endoscopic procedures. Clin Endosc 2022;55:581–587.ArticlePubMedPMCPDF
  • 10. U.S. Food and Drug Administration. BYFAVO (remimazolam) for injection, for intravenous use, CIV Initial U.S. Approval: 2020 [Internet]. U.S. Food and Drug Administration; 2020 [cited 2024 Jan 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212295s002lbl.pdf
  • 11. European Medicines Agency (EMA). Byfavo (remimazolam): summary of product characteristics [Internet]. EMA; 2021 [cited 2024 Jan 9]. Available from: https://www.ema.europa.eu/en/documents/product-information/byfavo-epar-product-information_en.pdf
  • 12. Antonik LJ, Goldwater DR, Kilpatrick GJ, et al. A placebo-and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. safety, efficacy, and basic pharmacokinetics. Anesth Analg 2012;115:274–283.ArticlePubMed
  • 13. Zhou Y, Hu P, Jiang J. Metabolite characterization of a novel sedative drug, remimazolam in human plasma and urine using ultra high-performance liquid chromatography coupled with synapt high-definition mass spectrometry. J Pharm Biomed Anal 2017;137:78–83.ArticlePubMed
  • 14. Stöhr T, Colin PJ, Ossig J, et al. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. Br J Anaesth 2021;127:415–423.ArticlePubMed
  • 15. Rogers WK, McDowell TS. Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures. IDrugs 2010;13:929–937.PubMed
  • 16. Eisenried A, Schüttler J, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: Part II. Pharmacodynamics of electroencephalogram effects. Anesthesiology 2020;132:652–666.ArticlePubMed
  • 17. Wiltshire HR, Kilpatrick GJ, Tilbrook GS, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg 2012;115:284–296.ArticlePubMed
  • 18. Rex DK, Bhandari R, Desta T, et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc 2018;88:427–437.ArticlePubMed
  • 19. Pambianco DJ, Borkett KM, Riff DS, et al. A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy. Gastrointest Endosc 2016;83:984–992.ArticlePubMed
  • 20. Rex DK, Bhandari R, Lorch DG, et al. Safety and efficacy of remimazolam in high risk colonoscopy: a randomized trial. Dig Liver Dis 2021;53:94–101.ArticlePubMed
  • 21. Park HJ, Kim BW, Lee JK, et al. 2021 Korean Society of Gastrointestinal Endoscopy clinical practice guidelines for endoscopic sedation. Clin Endosc 2022;55:167–182.ArticlePubMedPMCPDF
  • 22. Tan Y, Ouyang W, Tang Y, et al. Effect of remimazolam tosilate on early cognitive function in elderly patients undergoing upper gastrointestinal endoscopy. J Gastroenterol Hepatol 2022;37:576–583.ArticlePubMedPMCPDF
  • 23. Hu B, Jiang K, Shi W, et al. Effect of remimazolam tosilate on respiratory depression in elderly patients undergoing gastroscopy: a multicentered, prospective, and randomized study. Drug Des Devel Ther 2022;16:4151–4159.ArticlePubMedPMCPDF
  • 24. Kempenaers S, Hansen TG, Van de Velde M. Remimazolam and serious adverse events: a scoping review. Eur J Anaesthesiol 2023;40:841–853.ArticlePubMed
  • 25. Kanno Y, Ohira T, Harada Y, et al. Safety and recipient satisfaction of propofol sedation in outpatient endoscopy: a 24-hour prospective investigation using a questionnaire survey. Clin Endosc 2021;54:340–347.ArticlePubMedPDF
  • 26. Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy, Lichtenstein DR, Jagannath S, et al. Sedation and anesthesia in GI endoscopy. Gastrointest Endosc 2008;68:815–826.ArticlePubMed
  • 27. Pozin IE, Zabida A, Nadler M, et al. Respiratory complications during recovery from gastrointestinal endoscopies performed by gastroenterologists under moderate sedation. Clin Endosc 2023;56:188–193.ArticlePubMedPMCPDF
  • 28. Lu K, Wei S, Ling W, et al. Remimazolam versus propofol for deep sedation/anaesthesia in upper gastrointestinal endoscopy in elderly patients: a multicenter, randomized controlled trial. J Clin Pharm Ther 2022;47:2230–2236.ArticlePubMedPMCPDF
  • 29. Ye E, Wu K, Ye H, et al. Comparison of 95% effective dose of remimazolam besylate and propofol for gastroscopy sedation on older patients: a single-centre randomized controlled trial. Br J Clin Pharmacol 2023;89:3401–3410.ArticlePubMed
  • 30. Ahmer W, Imtiaz S, Alam DM, et al. Remimazolam versus propofol for sedation in gastrointestinal endoscopy and colonoscopy within elderly patients: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2024;80:493–503.ArticlePubMedPDF
  • 31. Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020;34:543–553.ArticlePubMedPDF
  • 32. Karavokiros KA, Tsipis GB. Flumazenil: a benzodiazepine antagonist. DICP 1990;24:976–981.ArticlePubMedPDF
  • 33. Yamamoto T, Kurabe M, Kamiya Y. Re-sleeping after reversal of remimazolam by flumazenil. J Anesth 2021;35:322.ArticlePubMedPDF
  • 34. Lin OS. Sedation for routine gastrointestinal endoscopic procedures: a review on efficacy, safety, efficiency, cost and satisfaction. Intest Res 2017;15:456–466.ArticlePubMedPMCPDF
  • 35. Delgado AA, de Moura DT, Ribeiro IB, et al. Propofol vs traditional sedatives for sedation in endoscopy: a systematic review and meta-analysis. World J Gastrointest Endosc 2019;11:573–588.ArticlePubMedPMC
  • 36. Qiu Y, Gu W, Zhao M, et al. The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: a randomized trial. Front Med (Lausanne) 2022;9:938940.ArticlePubMedPMC
  • 37. Lee J, Jeong S, Lee DH, et al. Finding the ideal sedative: a non-inferiority study of remimazolam vs propofol in endoscopic retrograde cholangiopancreatography. J Gastroenterol Hepatol 2023;38:2160–2166.ArticlePubMed

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Sedation in endoscopy: Current practices and future innovations
      Angelo Bruni, Giovanni Barbara, Alessandro Vitello, Giovanni Marasco, Marcello Maida
      World Journal of Gastrointestinal Endoscopy.2025;[Epub]     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Remimazolam, a novel drug, for safe and effective endoscopic sedation
      Clin Endosc. 2025;58(3):370-376.   Published online January 14, 2025
      DOI: https://doi.org/10.5946/ce.2024.026
      Close
    • XML DownloadXML Download
    Remimazolam, a novel drug, for safe and effective endoscopic sedation
    Remimazolam, a novel drug, for safe and effective endoscopic sedation
    Clinical trial no. 1. Outpatient colonoscopy (n=461)
    		 Clinical trial no. 2. High risk colonoscopy (n=162)
    Placebo+rescue Midazolam Remimazolam Placebo+rescue Midazolam Remimazolam
    Procedure success (%) 1.7 25.2 91.3 0.0 13.3 87.1
    Completion of procedure (%) 98.3 98.1 97.7 100.0 100.0 100.0
    Rescue therapy not required (%) 5.0 35.9 96.6 0.0 20.0 90.3
    Fully alert after end of procedure (min) 22.0 15.8 7.4 5.3 7.0 3.0
    Ready for discharge after end of procedure (min) 53.2 27.9 42.7 No report No report No report
    Back to normal after last dose (h) 9.5 9.2 5.5 No report No report No report
    Clinical trial no. 1. Upper gastrointestinal endoscopy in elderly patients (n=400)
    		 Clinical trial no. 2. Sedative-related adverse events in elderly patients undergoing gastroscopy (n=346)
    Propofol Remimazolam Propofol Remimazolam
    Sedation success (%) 100 100 100 99.4
    Time to loss of consciousness (s) No data No data 64 (50–80) 70 (58–92)
    Time to successful sedation (min) 2.1±0.4 2.1±0.4 No data No data
    Time to fully alert (min) 9.8±3.7 9.3±3.7 13.8±4.2 15.1±4.1
    Hypoxemia / apnea (%) 2 1 1.7 0.6
    Hypotension (%) 50.9 32.4 69.6 36.5
    Time to hospital discharge (min) No data No data 19.6±7.6 19.9±6.3
    Characteristic Propofol Midazolam Remimazolam
    Formulation Liquid Liquid Powder
    Pain on intravenous injection Painful No pain No pain
    Reversal agent No Flumazenil Flumazenil
    Cardiovascular and respiratory suppression ++ +/- +/-
    Active metabolite – + –
    Onset time (min) <1 3–5 1–2
    Recovery time (min) 10 20–80 10–40
    Metabolism Hepatic/extrahepatic Hepatic Tissue esterase
    Table 1. Clinical trials of remimazolam for procedural sedation in patients undergoing colonoscopy

    Table 2. Remimazolam versus propofol for procedural sedation in elderly patients undergoing gastroscopy

    Data are presented as mean±standard deviation, unless otherwise indicated.

    Table 3. Characteristics of propofol, midazolam, and remimazolam

    Table 1.

    Table 2.

    Table 3.

    Clin Endosc : Clinical Endoscopy Twitter Facebook
    © Korean Society of Gastrointestinal Endoscopy.
    Close layer
    TOP